US equities
|
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
SDEV
$7.48
▲+0.00%
WDC
$415.29
▲+0.00%
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
SDEV
$7.48
▲+0.00%
WDC
$415.29
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by MeiraGTx
MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors
September 23, 2026
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Reports Second Quarter 2026 Financial and Operational Results
August 13, 2026
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 06, 2026
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)
July 07, 2026
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 14, 2026
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Reports First Quarter 2026 Financial and Operational Results
May 14, 2026
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares
April 16, 2026
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)
April 16, 2026
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia
April 16, 2026
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026
April 14, 2026
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results
March 26, 2026
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Reports Third Quarter 2025 Financial and Operational Results
November 13, 2025
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology
November 10, 2025
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress
October 07, 2025
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Reports Second Quarter 2025 Financial and Operational Results
August 14, 2025
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting
May 13, 2025
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Reports First Quarter 2025 Financial and Operational Results
May 13, 2025
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease
May 09, 2025
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates
March 13, 2025
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson’s Disease and Industrialize MeiraGTx’s Proprietary Manufacturing Process
March 13, 2025
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy
February 21, 2025
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations
January 22, 2025
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia
December 09, 2024
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Announces Third Quarter 2024 Financial and Operational Results and Recent Business Updates
November 13, 2024
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Announces Five Posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress
October 22, 2024
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Announces Positive Data from Randomized, Sham-controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson’s Disease
October 15, 2024
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Announces Poster Presentation on a Potential Treatment for MC4R Genetic Deficiency at the 2024 Society for Neuroscience Conference
October 09, 2024
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter 2024 Financial and Operational Results
August 12, 2024
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Announces Pricing of Offering of Ordinary Shares Led by Sanofi
August 12, 2024
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
MeiraGTx Reports First Quarter 2024 Financial and Operational Results
May 09, 2024
From
MeiraGTx
Via
GlobeNewswire
Tickers
MGTX
